Mutation Profiling in Uterine Carcinosarcoma / Malignant Mixed Mullerian Tumors


Carcinosarcoma of the uterus (also known as malignant mixed Mullerian tumor, MMMT) is a highly aggressive form of uterine cancer.1-3 Even though it constitutes about 3-4% of uterine malignancy overall, it accounts for a disproportionate percentage of mortality associated with uterine malignancy. As its name implies, this is a biphasic (two-component) tumor which contains an admixture of carcinoma (cancer showing epithelial differentiation) and sarcoma (cancer showing mesenchymal differentiation) components. In the great majority of uterine carcinosarcoma, both the carcinoma and the sarcoma components are histologically high-grade. While a number of groups have previously demonstrated that the carcinoma and the sarcoma components represent the same disease based on X-chromosome inactivation pattern and TP53 hotspot mutation sequencing studies,4,5 it is not certain whether uterine carcinosarcoma starts out as carcinoma that undergoes sarcomatous transformation or as sarcoma that undergoes epithelial differentiation (similar to other biphasic sarcomas like synovial sarcoma).

We have previously demonstrated the presence of at least two major genetic types of uterine carcinosarcoma, each with its distinct gene mutation profiles (endometrioid carcinoma-like profile and serous carcinoma-like profile; see Figure 1),6 and we speculated as others have that uterine carcinosarcoma arises through sarcomatous transformation/transdifferentiation of a pre-existing uterine carcinoma, hence maintaining the mutation profiles of the pre-existing carcinoma.3,7

Carcinosarcomas or malignant mullerian mixed tumors (MMMT) contain malignant epithelial (carcinoma) and mesenchymal (sarcoma) components. These tumors can arise in any organ of the female genital tract such as vulva, vagina, cervix, endometrium, ovary or fallopian tube. Endometrium is the most common site. These tumors tend to occur in post-menopausal women although rarely are reported in younger women. Clinically, patients with uterine MMMT present with abnormal vaginal bleeding or pelvic or abdominal pain. Uterine carcinosarcomas generally have a worse prognosis compared to uterine carcinomas with a five year survival rate ranging from 5% to 40%. The most important prognostic factor is tumor stage.

The sarcomatous component may be either homologous or heterologous. The homologous component is usually non-specific high grade sarcoma in keeping with undifferentiated endometrial sarcoma. Heterologous elements include rhabdomyosarcoma, chondrosarcoma or osteosarcoma. Uterine carcinosarcomas follow the same staging system as uterine carcinomas.

Study Aims

  1. To more comprehensively characterize the mutation profiles of uterine carcinosarcomas through targeted sequencing.
  2. To compare the mutation profiles of the carcinoma and the sarcoma components in uterine carcinosarcoma to determine the relationship between the two components and the directionality of tumor progress.
  3. To compare the mutation profiles of primary uterine tumor (both carcinoma and sarcoma components) and metastatic tumor (peritoneal metastasis) to determine whether potentially targetable mutation(s) is present in all tumor sites.


We performed a comprehensive mutation analysis of 25 cancer genes that have been previously implicated in the oncogenesis of different uterine carcinomas and uterine sarcomas.6,8-13 These included ABCC9, AKT1, AKT2, AKT3, ARID1A, CCND1, CHD4, CSMD3, CTCF, CTNNB1, EP300, FBXW7, FGFR2, MAP3K4, MED12, PIK3CA, PIK3R1, PIK3R2, POLE, PPP2R1A, PTEN, SPOP, TP53, TSPYL2 and ZFHX3. The Illumina custom TruSeq amplicon panel was designed using Illumina’s DesignStudio and includes 1519 amplicons that cover nearly all exons of these 25 genes. We applied these analyses on a series of uterine carcinosarcomas with available frozen tumor tissue, formalin-fixed paraffin-embedded (FFPE) tumor tissue and normal tissue (Buffy coat). Libraries were constructed with genomic DNA extracted from matched tumor and normal tissue, pooled and run on the MiSeq (Illumina). In tumors with spatially distinct carcinoma and sarcoma components, we extracted DNA from the distinct carcinoma-only and sarcoma-only components, and analyzed these components separately. We also extracted DNA from metastatic tumor foci for comparison. All somatic non-synonymous mutations were manually checked in bam files using Integrated Genome Viewer.

Uterine carcinosarcomas exhibit mutation profiles similar to either uterine endometrioid-type or serous-type carcinomas.

With this set of 25 cancer genes, we identified the presence of somatic mutations (missense and non-sense point mutations, small insertions and deletions) in all primary uterine carcinosarcomas examined (n=30). The number of genes mutated ranged from 1 to 14 genes per tumor sample, with a median of 4 genes mutated per tumor (with a mutation variant frequency of at least 10% in the tumor sample). Based on the mutation profiles, we confirmed our prior observation that most uterine carcinosarcomas exhibit a mutation pattern that resembles that of either endometrioid-type carcinoma or serous-type carcinoma of the uterus. The endometrioid carcinoma-like mutation profile consisted of a clustering of PTEN, ARID1A, PIK3R1 and POLE mutations, while the serous carcinoma-like mutation profile consisted of a clustering of TP53, PPP2R1A, EP300 and FBXW7 mutations.

Endometrial cancer is not a single disease but is composed of multiple different subtypes which have differing risk factors, precursor lesions, genetic changes, treatment options and clinical outcomes. Typically the subtypes include endometrioid, serous, clear cell, undifferentiated and mixed carcinomas (those composed of more than one subtype)

Previously, targeted sequencing of exons from 9 genes: ARID1A, PPP2R1A, PTEN, PIK3CA, KRAS, CTNNB1, TP53, BRAF, and PPP2R5C in a large cohort of endometrial carcinomas highlighted distinct mutation profiles between subtypes. Grade 3 endometrioid carcinomas have significantly different frequencies of PTEN and TP53 mutations compared to low-grade counterparts. Uterine serous carcinoma and grade 3 endometrioid carcinomas have significantly different frequencies of mutations in PTEN, ARID1A, PPP2R1A, TP53, and CTNNB1. The genomic profile of carcinosarcomas suggests two distinct mutation profiles: endometrioid-type (PTEN, PIK3CA, ARID1A, KRAS mutations) and serous-type (TP53 and PPP2R1A mutations).6

Uterine carcinosarcoma occurs through sarcomatous transformation/transdifferentiation from uterine carcinomas

Report Figure 1: Schematic illustration for the development of uterine carcinosarcoma

Figure 1: Schematic illustration for the development of uterine carcinosarcoma

In nearly all the cases where the carcinoma and the sarcoma components were separately analyzed, we found that these components shared identical mutation(s) in at least one gene (1 to 11 genes, median of 2 genes), indicating a common ancestral origin (i.e. both components represent parts of the same tumor). There were a significantly greater number of genes mutated in the sarcoma component compared to the carcinoma component, indicating a carcinoma to sarcoma directionality of tumor progression. These findings suggest that the sarcoma component arose from pre-existing endometrial carcinoma of either endometrioid-genotype or serous–genotype (Figure 1). In a subset of uterine carcinomas that exhibits a mutation profile in keeping with an origin from endometrioid-type carcinoma, we observed high-frequency TP53 mutation in only the sarcoma component but not the carcinoma component, thus implicating TP53 mutation as being a candidate genomic event underlying the sarcomatous transformation phenomenon in endometrioid-genotype tumors.

There have been several proposed mechanisms by which carcinosarcomas may develop:

  1. The collision theory posits that the two elements, the carcinoma and the sarcoma, arise independently and collide to appear as a single tumor
  2. The combination theory claims that both tumor types arise from a single stem cell/progenitor cell that then differentiates into both sarcoma and carcinoma
  3. The conversion theory maintains that the sarcomatous elements evolves from the carcinoma

Genomic evidence of PI3K pathway dysregulation is common in uterine carcinosarcoma, and is present in both primary and metastatic tumor foci, hence representing a compelling therapeutic target

Figure 2: A representative case in which the carcinoma component and sarcoma component...

Figure 2: A representative case in which the carcinoma component and...

We observed frequent genomic evidence of PI3K pathway dysregulation in uterine carcinosarcomas. Mutations involving PI3K pathway regulatory genes were identified in 60% of all primary tumors, most commonly involving PIK3CA (50% of the tumors), followed by PTEN (30% of the tumors) and PIK3R1 (30% of the tumors). More importantly, these PI3K pathway gene mutations were shared by not only the carcinoma and the sarcoma components of the primary tumors, but also by the corresponding metastatic tumors (Figure 2). These findings indicate that PI3K pathway mutations occur relatively early on in the development of uterine carcinosarcoma (i.e. prior to sarcomatous transformation/transdifferentiation, and prior to tumor metastasis), and represent a common therapeutic target in the majority of uterine carcinosarcomas.

In a recent study, predictive biomarkers for single agent mTOR inhibitors were sought by profiling archival tumor samples from patients with recurrent or metastatic endometrial cancer who participated in phase 2 trials investigating single-agent mTOR inhibitors. Analyses included mutational profiling using the OncoCarta Panel version 1.0 and immunohistochemical expression of the tumor suppressor gene PTEN and stathmin, a marker of PI3K activation. No correlation was observed between biomarkers and tumor response or progression.14


Our findings provide further support that uterine carcinosarcomas arise through transdifferentiation of uterine carcinoma into sarcoma, and maintain the mutation profiles of the pre-existing uterine carcinoma (endometrioid carcinoma-like or serous carcinoma-like). We observed frequent PI3K pathway mutations in uterine carcinosarcoma which are acquired prior to tumor transdifferentiation and metastasis. These findings provide biologically compelling support for the use of therapy that target PI3K signaling and/or downstream pathway in the majority of uterine carcinosarcoma. Further functional studies that evaluate the effects of therapies targeting PI3K and/or downstream pathway in biologically representative experimental models of uterine carcinosarcoma is needed to determine the efficacy of this therapeutic strategy, both as a single therapy and when combined with conventional therapies.

By Melissa McConechy
Department of Pathology and Laboratory Medicine
University of British Columbia and BC Cancer Agency

David Huntsman, MD

Department of Pathology and Laboratory Medicine
University of British Columbia and BC Cancer Agency

Cheng-Han Lee, MD, PhD

Department of Laboratory Medicine and Pathology
University of Alberta and Royal Alexandra Hospital

Blaise Clarke, MD
Department of Pathology and Laboratory Medicine
University of Toronto


1. D'Angelo E, Prat J. Pathology of mixed Mullerian tumours. Best Pract Res Clin Obstet Gynaecol. 2011;25:705-718.

2. Kernochan LE, Garcia RL. Carcinosarcomas (malignant mixed Mullerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics. J Natl Compr Canc Netw. 2009;7:550-556; quiz 557.

3. Lopez-Garcia MA, Palacios J. Pathologic and molecular features of uterine carcinosarcomas. Semin Diagn Pathol. 2010;27:274-286.

4. Jin Z, Ogata S, Tamura G, et al. Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis. Int J Gynecol Pathol. 2003;22:368-373.

5. Wada H, Enomoto T, Fujita M, et al. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res. 1997;57:5379-5385.

6. McConechy MK, Ding J, Cheang MC, et al. Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol. 2012;228:20-30.

7. McCluggage WG. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer. 2002;12:687-690.

8. Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67-73.

9. Le Gallo M, O'Hara AJ, Rudd ML, et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet. 2012;44:1310-1315.

10. McConechy MK, Anglesio MS, Kalloger SE, et al. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J Pathol. 2011;223:567-573.

11. O'Hara AJ, Bell DW. The genomics and genetics of endometrial cancer. Adv Genomics Genet. 2012;2012:33-47.

12. Zhao S, Choi M, Overton JD, et al. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci U S A. 2013;110:2916-2921.

13. Kuhn E, Wu RC, Guan B, et al. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst. 2012;104:1503-1513.

14. Mackay HJ, Eisenhauer EA, Kamel-Reid S, et al.Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer. Cancer. Oct 2013(epub).

Somatic Mutation Profiling of PI3K Pathway in Uterine Carcinosarcoma/ Malignant Mixed Mullerian Tumors


Uterine carcinosarcoma (formerly called malignant mixed mullerian tumor) is a rare tumor of the gynecologic tract. It is classified as a mixed epithelial and mesenchymal tumor of the uterus in the 2003 World Health Organization classification. It accounts for <5% of uterine malignancies and typically arises in the uterine corpus or in the cervix.1 Rare cases arising in the ovary and fallopian tube have also been described.2,3 It is an aggressive neoplasm that has an extremely poor prognosis: 5-year survival is about 35%. Therapeutic options are limited and no specific targeted therapy is available.

These unusual tumors are a mixture of carcinoma (cancer of epithelial tissue) and sarcoma (cancer of mesenchymal /connective tissue). Targeted therapies aim to exploit known mutations specific to an individual patient’s tumor, rather than a generic targeting of rapidly dividing cells as it done by traditional chemotherapies.

Who gets uterine carcinosarcoma?

Plan Figure 1

Figure 1: Low power views showing a biphasic tumour...

Uterine carcinosarcoma affect postmenopausal women, with a higher incidence among African American women. Although it is a rare tumor with an incidence of 2 per 100,000 women per year, it accounts for a disproportionate percentage of uterine cancer-associated deaths. Risk factors associated with this disease are similar to those encountered in endometrial carcinoma, and include obesity and prolonged estrogen exposure. Some cases have been associated with prior radiotherapy.4

How do patient's present with this disease?

The clinical symptoms are essentially non-specific. The most common symptom is abnormal vaginal bleeding, or a bloody or watery discharge. Some patients may present with a mass or a bulky tumor which protrudes through the uterine cervix into the vagina. In addition to this, patients may have non-specific systemic symptoms such as fatigue. These are aggressive neoplasms and in 60% of patients the disease will have extended beyond the confines of the uterus at the time of presentation.

How is uterine carcinosarcoma diagnosed?

Plan Figure 2

Figure 2: High power views showing a biphasic tumour...

Once patients present with such symptoms they will undergo a uterine biopsy, and a pathologist will review the biopsy. Occasionally both components may not be sampled on biopsy and the final diagnosis will be rendered on the hysterectomy specimen. These are biphasic tumors showing an admixture of high grade carcinoma and sarcoma, although the exact volume and subtype of each component will vary (see Figures 1 & 2). The epithelial component may be endometrioid, serous and rarely clear cell or undifferentiated carcinoma. The sarcomatous component may be either homologous or heterologous. Homologous refers to the fact that the sarcomatous component is one which is native to the gynecologic tract and these typically include undifferentiated sarcoma, fibrosarcoma or leiomyosarcoma. Heterologous mesenchymal elements include rhabdomyosarcoma and chondrosarcoma with rare cases of liposarcoma, osteosarcoma and neurectodermal differentiation having been reported.4

Classification of Uterine Carcinoma

There are several different subtypes of endometrial cancer which include endometrioid carcinoma, serous carcinoma and clear cell carcinoma. Often endometrioid carcinoma is referred to as type I uterine cancer, and serous and clear cell carcinoma are referred to as type II.

Does the Type I Type II designation work?

The Type I and II designations describe loose ‘clinico-pathological clusters’ rather than firm diagnostic categories. Not all tumors fit neatly into this dualistic model; we have previously shown overlap between these categories.5 We performed clustering analysis of biomarkers on a cohort of endometrial cancers and demonstrated three prognostically-distinct groups. Cluster I consists predominantly of ER-positive low-grade endometrioid carcinomas and corresponds to Type I endometrial carcinoma. Cluster III consists predominantly of high-grade serous, clear cell, and mixed (serous and endometrioid) carcinomas, with a smaller number of high-grade endometrioid carcinomas; it has molecular features associated with Type II endometrial carcinoma and has the least favorable outcome. Cluster II included ER-positive tumors that showed p53, p21, and p27 expression. This group consists mainly of grades 2 and 3 endometrioid carcinomas, with a lesser number of mixed tumors and occasional serous and grade 1 endometrioid carcinomas. Cluster II prognosis was intermediate and, based on their immunoprofiles, these may represent Type I tumors that have progressed and become more aggressive over time. Carcinosarcomas are similar to Type II endometrial carcinoma (the most aggressive form) in many respects.

How do we treat patients with uterine carcinosarcoma?

These patients will be managed with complete surgical staging undergoing a total abdominal hysterectomy, bilateral salpingo-oophrectomy, pelvic and para-aortic lymphadenectomy, omentectomy biopsies of peritoneal surfaces and tumor debulking.1 If the tumor has spread widely at the time of diagnosis, surgical excision may not be possible. In addition to surgery, adjuvant radiation therapy and chemotherapy may be used. Radiation therapy reduces local pelvic recurrence but it is unclear whether there is improvement in overall survival.6,7,8 9 Since many of these patients will have disseminated disease and recur in a metastatic site, chemotherapy is used but there is uncertainty as to the best treatment.10,11,12,13 Multimodality therapy is often used with patients receiving both chemotherapy and radiation therapy.

The Clinical Problem

Despite extensive surgery and multimodality adjuvant therapy, these tumors have an extremely poor prognosis: 5-year survival is about 35%. There is no standard second line therapy and no specific targeted therapy is available. Traditional chemotherapies also have multiple side effects since they are targeting dividing cells, including normal cells. It is hoped that targeted therapeutics would be more effective in treating the tumor and cause less side effects. Given the limitations of surgery and radiotherapy, the only realistic hope for improving outcomes is improving chemotherapy.

Difficulties in Conducting Uterine Carcinosarcoma Research

Given the relatively low frequency of this disease within the population, intelligent trial design and drug selection is crucial when seeking to improve the outcome for women with this disease. Obtaining additional biological information that can guide selection of agents for investigation in this underserviced patient population is essential.

The Origin of Uterine Carcinosarcoma

A number of theories as to the cell of origin of such tumors has been proposed.14 The collision theory posits that these are biclonal synchronous tumors arising from separate tumour-initiating cells (TICs) that subsequently merge. The conversion theory posits that these are monoclonal tumors that arise from a single primitive TIC which undergoes divergent or metaplastic differentiation.

Molecular evidence suggests that most uterine carcinosarcomas are monoclonal.15, 16, 17 Accordingly, supported by molecular, epidemiologic, genetic, and histologic data, uterine carcinosarcomas are now regarded as high-grade carcinomas with sarcomatous/stromal differentiation, similar to other organ systems.18, 19 This is reflected in the use of platinum based treatment regimens similar to those used for uterine carcinomas.

Why is it so interesting that uterine carcinosarcoma may be a uterine carcinoma?

If uterine carcinosarcomas are closely related to high-grade endometrial carcinomas, insight into the molecular pathogenesis of the latter can be exploited to identify therapeutic targets in the former. Knowledge of such targets provides an opportunity for a directed but comprehensive analysis of the genetics of carcinosarcomas with the possibility of identifying similar targets.

So what can we learn from endometrial cancer?

We are developing a better understanding of the molecular development of endometrial cancer. Increasingly both type I and type II endometrial carcinoma are being found to have genetic alterations affecting the AKT/PI3K pathway, a pathway which may be targeted by therapeutic agents.20-25

Targeting the PI3K Pathway

Deletion of Phosphatase and tensin homologue on chromosome 10 (PTEN) is the most common genetic defect in endometrial cancer and is seen in up to 83% of tumours.26-28 PTEN is part of the PI3k/AKT pathway which is an important signaling pathway in cancers. mTOR is a kinase which functions downstream of PI3K/Akt and inhibition of this is seen as an important therapeutic target in cancers.29-31 Loss of PTEN causes deregulated PI3K/Akt/mTOR signalling which may provide neoplastic cells with a selective survival advantage by enhancing angiogenesis, protein translation and cell cycle progression.

Somatic mutations in uterine carcinosarcoma

Mutations of PIK3CA have recently been found in 36-39% of uterine endometrioid carcinomas and 15% of serous carcinomas.32, 33 Such mutations would collude with PTEN in promoting tumor. Other genetic alterations in endometrial cancer which would affect this pathway include K-ras mutations and these are found in 10-30% of type I endometrial cancers.34, 35

Thus targeting the PI3K/MTOR pathway alone and in combination in endometrial cancer is being actively exploited as a treatment strategy in this disease.36

Clinical Trials of Targeted Therapies in Endometrial Cancer

A recent clinical trial conducted by the National Cancer Institute of Canada (NCIC) investigating the MTOR inhibitor Temsirolimus, showed promising single agent activity in women with advanced and metastatic endometrial cancer.37 Deforolimus, is an intravenous mTOR inhibitor and in a phase II trial for women with uterine malignancies (endometrial cancer and uterine carcinosarcoma); 28% of patients demonstrated either a complete or partial response to this drug.38 Thus mTOR inhibitors do exhibit activity in women with advanced or recurrent endometrial cancer and carcinosarcoma.39-46

Using Sequenom Mass ARRAY System to Analyze the PI3K Pathway in Uterine Carcinosarcoma

New sequencing and profiling technologies are allowing us to unlock the paraffin archive of tumor samples stored in hospital pathology departments.47 One such technology is Sequenom matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) MassArray system.

The "pathology archive" is a term used to refer to the countless tissue samples which have been used for diagnostic purposes and are stored in pathology laboratories. Such samples are fixed in formalin and stored in paraffin blocks, hence they are sometimes referred to as the "paraffin archive." DNA in such samples tends to degrade, making it suboptimal for genetic analysis. New technologies such as the Sequenom Mass ARRAY system are able to overcome this and are able to analyze small quantities of degraded DNA derived from such archives. This allows analysis of some tumor types, by looking at samples collected over many years.

Sequenom MassARRAY: This system assays 20 different nucleotide variants (NVs) per well in a 384 well format. The MassARRAY can detect a NV even if it accounts for only 5% of the DNA. The Sequenom MassArray requires very little DNA, and can utilize degraded DNA like that obtained from formalin-fixed, paraffin-embedded tissues.

In this project we will be analyzing mutation profile of the genes involved in the PI3K pathway in an annotated cohort of 70 uterine carcinosarcomas.

Specific genes to be targeted: We will perform comprehensive genomic mutation analysis of the PI3K/Akt/mTOR pathway and other genes implicated in endometrial carcinogenesis using a customized Sequenom panel. The panel will include hot-spot mutations in members of the PI3k pathway such as AKT1, AKT2, AKT3, PDPK1, Rictor, FRAP, PHLPP2, PIK3R1 and PIK3CA. Other genes to be analysed include ALK, BRAK, CDK4, CTNNB1, EGFR, ERα, GNAS, HIF1A, IDH1, IGF1R, JAK2, KIT, KRAS, MEK1, MET, NRAS, PDGFR, RET, TNK, and STK11.


Uterine carcinosarcomas have poor prognosis and there are limited therapeutic options. This study will allow assessment of potential therapeutic targets in these cancers. Two recent publications provide strongly supportive data for this hypothesis. First, a group at Harvard has identified PIK3CA mutations in 19% of gynaecologic carcinosarcomas (uterine, ovarian, fallopian tube and vaginal) with mutations in the phosphatidylinositol 3-kinase pathway predominating in the uterine carcinosarcomas.48 Second, another group has identified a 20% rate of PIK3CA mutations in uterine MMMTs using Sequenom technology.49 This study will build on these observations by a comprehensive analysis of the PI3K pathway. If successful this will allow design of rational clinical trials for new treatments designed to target those abnormalities. In addition the study will contribute fundamental insights into the genetic alterations of these understudied tumors.

By Blaise Clarke, MD
Assistant Professor, Department of Pathology and Laboratory Medicine
University of Toronto

Katherine Stemke Hale, PhD
Director, MDACC CCSG Characterized Cell Line

Core Blake Gilks, MD
Professor, Department of Pathology and Laboratory Medicine
University of British Columbia

Paul Boutros, PhD
Assistant Professor, University of Toronto, Ontario
Institute of Cancer Research


1. Uterine carcinosarcoma. El-Nashar SA, Mariani A. Clin Obstet Gynecol. 2011 Jun;54(2):292-304.

2. Carcinosarcoma of the fallopian tube with metastasis of its epithelial component to the ovary, appendix and omentum. Piura B, Rabinovich A, Apel-Sarid L, Shaco-Levy R. J Obstet Gynaecol. 2009 Aug;29(6):566-7

3. Carcinosarcoma of the ovary: A case-control study. Rauh-Hain JA, Growdon WB, Rodriguez N, Goodman AK, Boruta DM 2nd, Schorge JO, Horowitz NS, Del Carmen MG. Gynecol Oncol. 2011 Jun 1;121(3):477-81.

4. Pathologic and molecular features of uterine carcinosarcomas. Lopez-Garcia MA, Palacios J. Semin Diagn Pathol. 2010 Nov;27(4):274-86.

5. Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. Alkushi A, Clarke BA, Akbari M, Makretsov N, Lim P, Miller D, Magliocco A, Coldman A, van de Rijn M, Huntsman D, Parker R, Gilks CB. Mod Pathol. 2007 Nov;20(11):1156-65.

6. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Reed NS, Mangioni C, Malmström H, Scarfone G, Poveda A, Pecorelli S, Tateo S, Franchi M, Jobsen JJ, Coens C, Teodorovic I, Vergote I, Vermorken JB; European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group. Eur J Cancer. 2008 Apr;44(6):808-18.

7. Clayton Smith D, Kenneth Macdonald O, Gaffney DK, et al. The impact of adjuvant radiation therapy on survival in women with uterine carcinosarcoma. Radiother Oncol. 2008;88:227–232.

8. Wright JD, Seshan VE, Shah M, et al. The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma. Am J Obstet Gynecol. 2008; 199:536.e1–536.e8.

9. Yoshinaga M, Togami S, Tsuji T, et al. Clinical outcome of metastatic uterine leiomyosarcoma and carcinosarcoma in a single institute. J Obstet Gynaecol Res. 2007;33:818–822.

10. Omura GA, Major FJ, Blessing JA. A randomized study of Adriamycin with and without dimethyl triazeoimidazole carboxamide in advanced uterine sarcomas. Cancer. 1983;52:626–632.

11. SuttonG, Brunetto VL, Kilgore L, et al. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group Study. Gynecol Oncol. 2000;79:147–153.

12. Wolfson AH, Brady MF, Rocereto T, et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) versus cisplatin- ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol. 2007;107:177–185.

13. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. Galaal K, Godfrey K, Naik R, Kucukmetin A, Bryant A. Cochrane Database Syst Rev. 2011 Jan 19;(1):CD006812.

14. Carcinosarcomas (malignant mixed Müllerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics. Kernochan LE, Garcia RL. J Natl Compr Canc Netw. 2009 May;7(5):550-6.

15. Molecular genetic aberrations of ovarian and uterine carcinosarcomas--a CGH and FISH study. Schipf A, Mayr D, Kirchner T, Diebold J. Virchows Arch. 2008 Mar;452(3):259-68.

16. TP53 mutational analysis supports monoclonal origin of biphasic sarcomatoid urothelial carcinoma (carcinosarcoma) of the urinary bladder. Armstrong AB, Wang M, Eble JN, MacLennan GT, Montironi R, Tan PH, Lopez-Beltran A, Zhang S, Baldridge LA, Spartz H, Cheng L. Mod Pathol. 2009 Jan;22(1):113-8.

17. Carcinosarcoma of monoclonal origin arising in a dermoid cyst of ovary: a case report. Cabibi D, Martorana A, Cappello F, Barresi E, Di Gangi C, Rodolico V. BMC Cancer. 2006 Mar 1;6:47.

18. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. McCluggage WG. Int J Gynecol Cancer. 2002 Nov-Dec;12(6):687-90.

19. Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? McCluggage WG. J Clin Pathol. 2002 May;55(5):321-5.

20. PI3K pathway-directed therapeutic strategies in cancer. Agarwal R, Carey M, Hennessy B, Mills GB. Curr Opin Investig Drugs. 2010 Jun;11(6):615-28.

21. Individualized molecular medicine: linking functional proteomics to select therapeutics targeting the PI3K pathway for specific patients. Murph MM, Smith DL, Hennessy B, Lu Y, Joy C, Coombes KR, Mills GB. Adv Exp Med Biol. 2008;622:183-95.

22. Exploiting the PI3K/AKT pathway for cancer drug discovery. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Nat Rev Drug Discov. 2005 Dec;4(12):988-1004.

23. Targeting PI3K-AKT pathway for cancer therapy. Lu Y, Wang H, Mills GB. Rev Clin Exp Hematol. 2003 Jun;7(2):205-28.

24. PI3K/AKT/mTOR inhibitors in ovarian cancer. Mazzoletti M, Broggini M. Curr Med Chem. 2010;17(36):4433-47.

25. PI(3)king apart PTEN's role in cancer. Zhang S, Yu D. Clin Cancer Res. 2010 Sep.

26. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, Weng LP, Eng C. J Natl Cancer Inst. 2000 Jun 7;92(11):924-30.

27.  High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Stambolic V, Tsao MS, Macpherson D, Suzuki A, Chapman WB, Mak TW. Cancer Res. 2000 Jul 1;60(13):3605-11.

28. PTEN1 is frequently mutated in primary endometrial carcinomas. Kong D, Suzuki A, Zou TT, Sakurada A, Kemp LW, Wakatsuki S, Yokoyama T, Yamakawa H, Furukawa T, Sato M, Ohuchi N, Sato S, Yin J, Wang S, Abraham JM, Souza RF, Smolinski KN, Meltzer SJ, Horii A. Nat Genet. 1997 Oct;17(2):143-4.

29. PTEN and the PI3-kinase pathway in cancer. Chalhoub N, Baker SJ. Annu Rev Pathol. 2009;4:127-50.

30. Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Brader S, Eccles SA. Tumori. 2004 Jan-Feb;90(1):2-8.

31. Akt signalling in health and disease. Hers I, Vincent EE, Tavaré JM. Cell Signal. 2011 May 17
32. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Oda K, Stokoe D, Taketani Y, McCormick F. Cancer Res. 2005 Dec 1;65(23):10669-73.

33. Uterine papillary serous carcinoma: epidemiology, pathogenesis and management. Fader AN, Boruta D, Olawaiye AB, Gehrig PA. Curr Opin Obstet Gynecol. 2010 Feb;22(1):21-9.

34. Differences in patterns of TP53 and KRAS2 mutations in a large series of endometrial carcinomas with or without microsatellite instability. Swisher EM, Peiffer-Schneider S, Mutch DG, Herzog TJ, Rader JS, Elbendary A, Goodfellow PJ. Cancer. 1999 Jan 1;85(1):119-26.

35. Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma. Sasaki H, Nishii H, Takahashi H, Tada A, Furusato M, Terashima Y, Siegal GP, Parker SL, Kohler MF, Berchuck A. Cancer Res. 1993 Apr 15;53(8):1906-10.

36. Promising novel therapies for the treatment of endometrial cancer. Gehrig PA, Bae-Jump VL. Gynecol Oncol. 2010 Feb;116(2):187-94.

37. Oza AM, Elit L, Provencher D, et al. A Phase II study of temsirilimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy. J Clin Oncol 2008;26:5516.

38. Colombo N, McMeekin DS, Schwartz P, Kostka, Sessa C, Gehrig PA, et al. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. Proc Am Soc Clin Oncol 2007;25:5516.

39. Evaluating temsirolimus activity in multiple tumors: a review of clinical trials. Dancey JE, Curiel R, Purvis J. Semin Oncol. 2009 Dec;36 Suppl 3:S46-5.

40. Management of advanced-stage and recurrent endometrial cancer. Ray M, Fleming G. Semin Oncol. 2009 Apr;36(2):145-54.

41. Molecule-targeted agents in endometrial cancer. Delmonte A, Sessa C. Curr Opin Oncol. 2008 Sep;20(5):554-9.

42. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Bansal N, Yendluri V, Wenham RM. Cancer Control. 2009 Jan;16(1):8-1.

43. Targeted therapies in gynecologic cancers and melanoma. Ortega E, Marti RM, Yeramian A, Sorolla A, Dolcet X, Llobet D, Abal L, Santacana M, Pallares J, Llombart-Cussac A, Matias-Guiu X. Semin Diagn Pathol. 2008 Nov;25(4):262-73.

44. Molecular target therapies in endometrial cancer: from the basic research to the clinic. Gadducci A, Tana R, Cosio S, Fanucchi A, Genazzani AR. Gynecol Endocrinol. 2008 May;24(5):239-49.

45. Systemic therapy in metastatic or recurrent endometrial cancer. Pectasides D, Pectasides E, Economopoulos T. Cancer Treat Rev. 2007 Apr;33(2):177-90. Epub 2006 Dec

46. The biology and clinical relevance of the PTEN tumor suppressor pathway. Sansal I, Sellers WR. J Clin Oncol. 2004 Jul 15;22(14):2954-63

47. Unlocking the molecular archive: the emerging use of formalin-fixed paraffin-embedded tissue for biomarker research in urological cancer. Gnanapragasam VJ. BJU Int. 2010 Jan;105(2):274-8.

48. Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin. Growdon WB, Roussel BN, Scialabba VL, Foster R, Dias-Santagata D, Iafrate AJ, Ellisen LW, Tambouret RH, Rueda BR, Borger DR. Gynecol Oncol. 2011 Apr;121(1):212-7.

49. Abstract 1004 USCAP 2011: Molecular Alterations in Endometrial Carcinosarcomas (ECS). Michele Biscuola, Koen Van De Vijver, Maria Angeles Castilla, Laura Romero-Perez, Maria Angeles Lopez-Garcia, Jose Palacios, Esther Oliva. Hospital Universitario Virgen del Rocío-IBIS (Instituto de Biomedicina de Sevilla), Seville, Spain; Massachusetts General Hospital, Boston.

  • Figures 1 & 2: Low and high power views showing a biphasic tumour composed of malignant glands (carcinoma) and adjacent malignant stromal cells (sarcoma),
  • Figures 1 & 2: Low and high power views showing a biphasic tumour composed of malignant glands (carcinoma) and adjacent malignant stromal cells (sarcoma),
  • Report Figure 1
    Schematic illustration for the development of uterine carcinosarcoma
  • Report Figure 2
    A representative case in which the carcinoma component and sarcoma component of the primary uterine carcinosarcoma, and its peritoneal metastasis were analyzed separately, and they also harboured identical PIKCA and PTEN mutations.

Grant Funding

The Liddy Shriver Sarcoma Initiative announced the funding of this $50,000 grant in June 2011. The study was made possible by a generous donation from Dr. Laura Somerville, by generous donations made in memory of Adrianne Pfeiffer (through several MMMT awareness events organized by her husband, Robert Pfeiffer), and by generous donations made in memory of Mary Anne Voeglie.